Spark hemophilia B gene therapy clears another early test – FierceBiotech
FierceBiotech |
Spark hemophilia B gene therapy clears another early test
FierceBiotech Spark Therapeutics has posted fresh data from a phase 1/2 trial of its hemophilia B gene therapy, SPK-9001. The data suggest Spark’s tapering courses of steroids successfully arrested the factor IX (FIX) declines seen in two patients who appeared to … Spark carefully records a safe step forward for closely-watched hemophilia gene therapyEndpoints News Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and …GlobeNewswire (press release) |
Express.co.uk |
Making life FROM SCRATCH? Scientists on brink of technological breakthrough
Express.co.uk Technology pioneers are now taking notice, with record sums of money moving into a field which could deliver novel drugs, materials, chemicals and even perfumes. Despite ethical and safety concerns, investors are attracted by synthetic biology’s wide … Synthetic Biology Market Value Share, Supply Demand, share and Value Chain 2016-2026MilTech |
Myeloma Research News |
Poseida’s P-BCMA-101 Eliminates Tumors in Mice with Multiple Myeloma, Studies Show
Myeloma Research News Usually, CAR T-cells are engineered to express an antibody that recognizes the cancer protein. Poseida has developed a new approach that it believes is more stable and less immunogenic — that is, doesn’t induce immune responses against the engineered … |
Equities.com |
Asterias (AST): Blazing the Stem Cell Trail for Spinal Cord Injury
Equities.com Yesterday we highlighted the GTCbio Stem Cell Summit in Boston. Another company we’ve been closely following is also represented at the conference, Asterias Biotherapeutics (NYSE: AST). Asterias is developing therapies based on pluripotent stem cells … |
Genetic Literacy Project |
Pro-life movement poses obstacles for CRISPR editing of human embryos
Genetic Literacy Project It’s hard to discuss CRISPR without discussing, even tangentially, the issue of abortion. The gene editing technology has now been applied to viable human embryos, opening up a door to editing genetic code in future humans. But there’s an age-old … |